1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia

Medtech innovation briefing [MIB278] Published: 30 November 2021

  • Overview
  • Summary
  • The technology
  • Regulatory information
  • Equality considerations
  • Clinical and technical evidence
  • Expert comments
  • Expert commentators
  • Development of this briefing
Download (PDF)

Advice

  • Next

NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia.

What are MIBs?


  • Next